MediciNova reports positive MS data

MediciNova’s MN-166 shows positive risk reduction in progressive MS

MediciNova reports positive MS data.
MediciNova reports positive MS data

MediciNova (MNOV) announced the presentation of additional positive clinical data from the SPRINT-MS Phase 2b Trial of MN-166 – ibudilast – in progressive multiple sclerosis, conducted through the National Institutes of Health-sponsored NeuroNEXT network.

MN-166 demonstrated a 26% reduction in the risk of confirmed disability progression compared to placebo.

Confirmed disability progression was a secondary endpoint in this Phase 2b trial but would be considered a primary endpoint in Phase 3.

MediciNova’s power analysis has determined that a Phase 3 trial of MN-166 that enrolls approximately 700 subjects will be sufficiently powered to achieve statistical significance for confirmed disability progression.

As reported in October 2017, the SPRINT-MS Phase 2b Trial of MN-166 in progressive MS achieved both primary endpoints. MN-166 (ibudilast) demonstrated a statistically significant 48% reduction in the rate of progression of whole brain atrophy compared to placebo, and demonstrated a favorable safety and tolerability profile.

The most common treatment-emergent adverse events during the study were gastrointestinal adverse events, which occurred with a higher frequency in the MN-166 group, and upper respiratory tract infections, which occurred with a higher frequency in the placebo group.

The MN-166 (ibudilast) portfolio, which includes the Phase 2-staged lead drug compound and proprietary analogs, represents novel, first-in-class, non-opioid drugs for the treatment of drug addiction, progressive multiple sclerosis and pain.

MN-166 is a first-in-class, orally bioavailable, small molecule glial attenuator that suppresses pro-inflammatory cytokines IL-1ß, TNF-a, and IL-6, and may upregulate the anti-inflammatory cytokine IL-10.

MNOV closed at $8.32.


To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners

This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Leave a Reply

Your email address will not be published. Required fields are marked *

Translate »